Pages that link to "Q725307"
Jump to navigation
Jump to search
The following pages link to pharmacodynamics (Q725307):
Displayed 50 items.
- pharmacology (Q128406) (← links)
- Category:Pharmacodynamics (Q8760220) (← links)
- (Q10280074) (redirect page) (← links)
- (Q13174131) (redirect page) (← links)
- (Q19794824) (redirect page) (← links)
- Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles (Q22241778) (← links)
- Lithium: the pharmacodynamic actions of the amazing ion (Q22241779) (← links)
- Amphetamine-Type Medicines: A Review of Pharmacokinetics, Pharmacodynamics, and Toxicological Aspects (Q22305780) (← links)
- Development of a physiologically based pharmacokinetic and pharmacodynamic model to determine dosimetry and cholinesterase inhibition for a binary mixture of chlorpyrifos and diazinon in the rat (Q23910753) (← links)
- Pharmacokinetic and pharmacodynamic interaction for a binary mixture of chlorpyrifos and diazinon in the rat (Q23910754) (← links)
- Age-dependent pharmacokinetic and pharmacodynamic response in preweanling rats following oral exposure to the organophosphorus insecticide chlorpyrifos (Q23910755) (← links)
- Monte Carlo analysis of the human chlorpyrifos-oxonase (PON1) polymorphism using a physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model (Q23910756) (← links)
- An age-dependent physiologically based pharmacokinetic/pharmacodynamic model for the organophosphorus insecticide chlorpyrifos in the preweanling rat (Q23911011) (← links)
- Pharmacokinetics and pharmacodynamics of chlorpyrifos and 3,5,6- trichloro-2-pyridinol in rat saliva after chlorpyrifos administration (Q23915380) (← links)
- Effect of in vivo nicotine exposure on chlorpyrifos pharmacokinetics and pharmacodynamics in rats (Q23921511) (← links)
- Physiologically based pharmacokinetic/pharmacodynamic model for the organophosphorus pesticide diazinon (Q23922265) (← links)
- Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy (Q24519008) (← links)
- The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone (Q24538601) (← links)
- Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor (Q24538612) (← links)
- Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa (Q24538637) (← links)
- Pharmacodynamic profile of bisoprolol, a new beta 1-selective adrenoceptor antagonist (Q24540330) (← links)
- Pharmacodynamic and pharmacokinetic studies on bufuralol in man (Q24540333) (← links)
- A placebo controlled double-blind evaluation of the pharmacodynamics of fengabine vs amitriptyline following single and multiple doses in elderly volunteers (Q24541293) (← links)
- Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics (Q24564974) (← links)
- Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin (Q24605776) (← links)
- Pharmacodynamic considerations for moderate and deep sedation (Q24613149) (← links)
- Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease (Q24613855) (← links)
- Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability (Q24628212) (← links)
- Chenodeoxycholate in Females With Irritable Bowel Syndrome-Constipation: A Pharmacodynamic and Pharmacogenetic Analysis (Q24635181) (← links)
- Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study (Q24642002) (← links)
- Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer (Q24645548) (← links)
- Recommended reading in population pharmacokinetic pharmacodynamics (Q24647906) (← links)
- Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate (Q24650169) (← links)
- A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points (Q24651047) (← links)
- Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide (Q24651117) (← links)
- Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach (Q24652176) (← links)
- In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model (Q24654780) (← links)
- Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers (Q24658008) (← links)
- Assessment of the pharmacodynamic properties of antimalarial drugs in vivo (Q24670346) (← links)
- Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection (Q24672964) (← links)
- Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects (Q24673411) (← links)
- 1-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect (Q24673559) (← links)
- Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol (Q24673617) (← links)
- The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects (Q24678717) (← links)
- Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects (Q24678775) (← links)
- Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam (Q24679467) (← links)
- Drug therapy in dental practice: general principles. Part 2 - pharmacodynamic considerations (Q24680020) (← links)
- Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands (Q24680373) (← links)
- Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of drugs - method development and application to magnesium in sheep (Q24805651) (← links)
- Offset of pharmacodynamic effects and safety of remifentanil in intensive care unit patients with various degrees of renal impairment (Q24806101) (← links)